Comparison of clinical, para-clinical and laboratory findings in survived and deceased patients with COVID-19: diagnostic role of inflammatory indications in determining the severity of illness by Rokni, M. et al.
RESEARCH ARTICLE Open Access
Comparison of clinical, para-clinical and
laboratory findings in survived and
deceased patients with COVID-19:
diagnostic role of inflammatory indications
in determining the severity of illness
Mohsen Rokni1* , Kazem Ahmadikia2*, Somaye Asghari3, Shahabodin Mashaei4 and Fahimeh Hassanali5
Abstract
Background: Since December 2019, when a cluster of pneumonia cases due to SARS-CoV-2 initially emerged in
Wuhan city and then rapidly spread throughout the world, the necessity for data concerning the clinical and para-
clinical features of Iranian patients with COVID-19 was highlighted. Therefore, we aimed to compare the clinical,
para-clinical and laboratory evidences of deceased patients with survival group.
Methods: We extracted data regarding 233 patients with laboratory-confirmed COVID-19 from Buali Hospital in
Iran; clinical/para-clinical and inflammatory indexes data were collected and analyzed. The data of laboratory
examinations and chest CT findings were compared between deceased and survived patients.
Results: The mean age of the patients was 49.8 years and 64% of our patients were male. The acute respiratory
distress syndrome occurred in 64 patients, 52 who were admitted to the ICU, which all of them underwent invasive
mechanical ventilation, and 28 who died. Lymphopenia (79%), neutrophilia (79%), and thrombocytopenia (21%)
were the most frequently observed laboratory findings of the deceased group on admission. Most patients (68%)
had a high systematic immune-inflammation (SII) index of > 500 and increased C-reactive protein level (88%). Levels
of inflammatory indexes such as neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and SII
were documented to be significantly elevated in the deceased group when compared with the patients who
survived (P < 0.0001, P < 0.001, P < 0.0001, respectively). The most commonly presented symptoms were fever (70%)
and cough (63%) on admission. Headache was uncommon (11%). Ground-glass opacity with consolidation (mixed)
was the most common radiologic finding on chest CT (51%). No radiographic or CT abnormality was found in 15 of
204 patients (7%).
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Conclusion: Small fraction of patients with COVID-19 may present without fever and abnormal radiologic findings.
Elevated NLR, PLR and SII can be considered as prognostic and risk stratifying factor of severe form of disease.
Keywords: COVID-19, SARS-CoV-2, Acute lung injury, Pneumonia, Cytokine storm syndrome, Immune response,
Inflammation mediators, ARDS, Ground-glass opacities, Iran
Background
In late December 2019, a cluster of unknown pneumonia
cases reported in Wuhan, China. A few days later, the
causative agent of this mysterious pneumonia was recog-
nized as a novel betacoronavirus. Subsequently, The
causative virus called as severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2) and the relevant
disease termed as corona virus disease 2019 (COVID-19)
by the World Health Organization (WHO) [1, 2]. At
present, the cases of COVID-19 have been detected in
many countries around the world. According to the
latest data, up to the Aug 30, 2020, the numbers of
laboratory-confirmed cases in Iran reached 371,816 of
which 21,359 were unfortunately deceased, and 321,421
were recovered. Also 3759 were severe illness. The
number of laboratory-confirmed cases in other countries
also reached 24,854,140 of which 838,924 were died,
according to official data from the WHO.
Many previous studies have shown that COVID-19
patients have significant inflammatory responses, accom-
panied by a decrease in the absolute count of lympho-
cytes in the peripheral blood circulation and an
enhancement in the number of neutrophil [3]. Mild/
moderate form of SARS-CoV-2 infection is the major
clinical form of the infection that is characterized by
fever, malaise, cough, upper respiratory symptoms, and
with or without dyspnea. Therefore, most of these pa-
tients do not need hospitalization [4]. However, nearly
15–20% of cases, who show prominent abnormalities in
laboratory findings predicting disease deterioration,
would develop severe form of the disease which majorly
need to be intensively cared and hospitalization in inten-
sive care unit (ICU) [5, 6]. Organ dysfunction including
acute respiratory distress syndrome (ARDS), shock,
acute cardiac injury and acute renal injury, may occur in
5% of severe cases with COVID-19 [4, 7]. Since, majority
of COVID-19 patients show lung involvement on com-
puted tomography (CT) scan imaging patterns, radio-
logical (X ray) examinations have become essential
diagnostic method in early detection and assessment of
disease progression [8]. Typical chest CT scan findings
of COVID-19 include peripherally distributed multifocal
ground-glass opacities (GGOs) with patchy consolida-
tions and posterior part or lower lobe involvement pre-
dilection [9]. Increasing numbers of pulmonary lesions
extent and density of GGOs on CT scan show disease
progression [7, 9]. The pathological damages caused by
the virus could stimulate a series of inflammatory re-
sponses and uncontrolled production of inflammatory
cytokines e.g. interleukin (IL)-1, IL-6 and TNF-α, the
recruitment of inflammatory macrophages and granulo-
cytes, leading to cytokines storm (CSS), termed as a sec-
ondary hemophagocytic lymphohistiocytosis (sHLH) or
macrophage activation syndrome, which may follow by
disease deterioration, ARDS, septic shock and eventually
multiple organ system failure (MOSF) in some patients
[10]. Various studies suggested that genes polymor-
phisms (SNP) of inflammatory interleukin and chemo-
kine are likely associated with genetic susceptibility to
SARS-CoV-2, and probably is responsible for developing
different form of COVID-19 in different individuals [11,
12].
In this study, we compared the clinical/laboratory find-
ings, imaging manifestation and outcomes of the disease
in clinically classified groups including non-severe and
severe (consequently death) COVID-19 patients, to find
potential prognostic indications contributing to an
accurate assessment of the COVID-19 severity.
Methods
Design and participants
This cross-sectional study was performed in referral hos-
pital for COVID-19 patients in Zahedan, Iran. Clinical
and paraclinical data regarding 233 laboratory confirmed
cases of COVID-19 who were hospitalized in our
hospital from February 29, 2020 to May 24, 2020 were
subjected in the analysis. A verified case of COVID-19
was defined as a positive result on real-time reverse-
transcriptase polymerase chain reaction (RT-PCR) assay
of naso-pharyngeal or oro-pharyngeal swab specimens.
The protocol of the present study was approved by the
ethical committee of ZAUMS, and written consent was
obtained from the patients or their guardians. The
criteria of clinically based classification of our subjects
were as follows, mild/moderate (non-severe) form
characterizing with the respiratory distress or oxygen
saturation ≤ 93%, or severe form if at least one of the
following conditions presented: SpO2 ≤ 90%, if respira-
tory failure occurred and mechanical ventilation was
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required, shock occurred or ICU admission was
required.
Data collection
From all suspected patients with SARS-CoV-2 infection
that were admitted to be hospitalized in infectious unit,
oro- and naso-pharyngeal swab specimens were col-
lected and stored in virus transport medium (VTM). In
addition, fasting venous blood specimen was collected
for para-clinical assessment.
For all of the patients, routine blood biochemistry pa-
rameters, complete cell blood count (CBC), C-reactive
protein (CRP), erythrocyte sedimentation rate (ESR) and
chest radiological/CT scan were performed. Routine
blood biochemistry analyses included liver function test
(LFT), renal function, electrolytes test, lactate dehydro-
genase (LDH), myocardial enzymes e.g. creatine phos-
phokinase (CPK), D-Dimer and status of other virus
infection.
Real-time reverse transcription polymerase chain reaction
assay
Viral ribonucleic acid was extracted from the oro- and
naso-pharyngeal swab samples using the COVID-19
ORF1ab/N (two regions, so four sequences of primer
should be presented) gene nucleic acid detection kit
(manual).
Real-time RT-PCR assays for SARS-CoV-2 RNA de-
tection were performed using Quanti Nova Probe RT-
PCR Kit (Qiagen) in a Light Cycler 480 Real-Time PCR
System (Roche, Basel, Switzerland) as previously de-
scribed [13]. Each 20 μl reaction mixture contained 10 μl
of 2 × Quanti Nova Probe RT-PCR Master Mix, 0.2 μl of
QN Probe RT-Mix, 1.6 μl of each 10 μM forward and re-
verse primer, 0.4 μl of 10 μM probe, 1.2 μl of RNase-free
water and 5 μl of RNA as the template. The thermal cyc-
ling condition was 10min at 45 °C for reverse transcrip-
tion, 5 min at 95 °C for PCR initial activation, and 40
cycles of 94 °C for 10 s and 58 °C for 30 s. According to
the cycle threshold (Ct) analysis, if the Ct values of the
fluorescein amidites (FAM) channel and victoria (VIC)
channel were ≤ 37, and the curve is S-shaped with a sig-
nificant exponential growth period, the test result speci-
men regarded as positive, if the Ct value of one channel
was ≤ 37, the specimen tested again. If the Ct values of
both channels are > 37, and the internal standard chan-
nel test result was positive, then the test result specimen
regarded as negative.
Inflammatory indications
Inflammatory indexes were detected using specific pa-
rameters of blood analysis. These indexes were as fol-
lows: neutrophil to lymphocyte ratio (NLR) by dividing
the neutrophil absolute count to the lymphocyte
absolute count and platelet to lymphocyte ratio (PLR) by
dividing the platelet count to the lymphocyte absolute
count were defined. Systematic immune-inflammation
index (SII) was calculated as follows: platelet count ×
NLR (per μL).
Statistics analysis
All of the data presented by mean ± standard error of
mean (SEM). Analysis was performed with the IBM
SPSS version 23.0 statistical software package, with an
independent sample t test for comparison between
groups. Descriptive statistics were performed to deter-
mine the patient’s diagnostic and clinical features. P-
value less than 0.05 were indicated statistically
significant.
Results
A total of 1911 patients with non-severe or severe symp-
toms of COVID-19 during 3 month were admitted in
our hospital, of these cases, laboratory diagnosis of 233
patients was confirmed with RT-PCR method. About
12% (28/233) of patients with confirmed diagnosis of
this disease were died. Therefore, during the same time,
the rate of mortality for all causes in our hospital was
2.04% (39/1911). Of the 233 patients with SARS-CoV-2
infection included in this study, 205 patients were diag-
nosed as non-severe or severe form of disease (survival
group). However, 28 out of 73 who were suffering from
severe form of disease, eventually expired (deceased
group, [see Table 1]). The mean age of two survival
group and deceased group were 47.6 versus 65.3 years,
respectively, which was statistically significant different
(P < 0.0001). Most of the deceased cases (71.4%) and sur-
vival cases (62.9%) were male. Also the mean age of the
all patients was 49.8 years.
Clinical and laboratory findings
As indicated in Table 2, fever > 38°c (70%) and dry
cough (63%) were the main common symptoms on ad-
mission. Dyspnea (62%), SpO2 < %93 (55%) and muscle
(32%) or chest (22%) pain were also observed in some
patients. Regarding deceased groups, 71% of the infected
patients were men (20 cases) and more than half had
underlying diseases (16 patients, 64%), including hyper-
tension (seven, 25%), diabetes (six, 21%), renal and car-
diovascular disease (three, 11% [Table 3]).
On the admission, lymphopenia (lymphocyte count
lower than 1100 μl) (58%), neutrophilia (absolute neutro-
phil count more than 6300 μl) (25%), and
thrombocytopenia (< 125 × 109 per L, 12.4%) were the
most principal laboratory abnormalities in our subjects.
Regarding survival group, elevated levels of CRP (87.3%),
LDH (97.4%), ESR (90.7%), CPK (35%), NLR more than
5 (33.7%), PLR higher than 200 (40.9%), SII index of
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rather than 500 (64.9%) were recorded. However, in the
deceased group, NLR more than 5, PLR higher than 200
and elevated SII were documented in 93, 71.4 and 93%
of the patients, respectively. Furthermore, 79% of de-
ceased patients had lymphopenia. Therefore, NLR, PLR
and SII indexes were chosen to be statistically analyzed
as the most useful prognostic factor for disease deterior-
ation and severity prediction (Table 4).
Independent sample t test show that the inflammatory
indicator levels were significantly elevated in the patients
with non-severe or severe COVID-19 (survival group)
when compared with the deceased group (NLR; P <
0.0001, PLR; P < 0.001, SII; P < 0.0001) (Table 5). In
addition, serum BUN and creatinine levels in group de-
ceased were significantly increased when compared with
the survival group (P < 0.0001).
Radiography findings
Radiological data is summarized in Table 6. The typical
chest CT patterns of patients with proven COVID-19,
were GGO pattern (30.3%), patchy consolidations
(11.4%, Fig. 1a) and GGO with consolidations (mixed,
51.2% [see Fig. 1b]). Pure GGO lesions (Fig. 1c, I, II) can
be the early appearance of SARS-CoV-2 pneumonia.
Ground-glass opacity with consolidation (mixed, 89%)
was the most frequently observed radiography finding of
the deceased group. Interestingly, 15 (7.1%) of partici-
pants had clear chest CT scan findings on admission.
Except NLR and SII indicators (P < 0.01), there was no
statically significant difference in indicators of systemic
inflammation of patients who had GGO in comparison
with those who had mixed pattern on lung CT (Supple-
mentary Figure 1).
Discussion
Current study is a descriptive report on the clinical/
para-clinical characteristics of 233 patients with labora-
tory proven evidence of COVID-19 attending Buali
Hospital, Zahedan, Iran. It represents the recent status
of the COVID-19 in east of Iran where biggest state of
Iran is located. Collectively, 1911 patients who were




Stat N = 233
Age, years 16–40 Y 77 (33.1%)
40–60 Y 84 (36.1%)





Intubation ICU 52 (22%)
EMS 12 (5.2%)
Recharge 205 (88%)
Severe Pneumonia 73 (31.1%)
Non-severe Pneumonia 160
(68.9%)
Total Patients Referred 1911
Total Hospitalization 629
Transfer to ICU 73
Total RT-PCR Test 1259
Positive RT-PCR 233
Chest CT-SCAN 3266
Follow up Recurrence after
recovery
7
Death after Recharge 2
Table 2 Signs and symptoms at admission of COVID-19
patients
Signs and symptoms Overall (N = 233)
Fever over 38°c 137 (69.6%)
Dry Cough 124 (62.6%)
Dyspnea 123 (62.1%)
Muscle Pain 63 (31.8%)
Chest Pain 30 (21.8%)




SpO2 < %93 128 (54.9%)
SpO2 > %93 105 (45.1%)
Table 3 Baseline characteristics of patients infected with
COVID-19
Any Comorbidity Survival (N = 205) Deceased (N = 28)
Gender
Male 129 (62.9%) 20 (71.4%)
Female 76 (37.1%) 8 (28.6%)
Diabetes 32 (15.6%) 6 (21.4%)
Hypertension 30 (14.6%) 7 (25.1%)
Cardiovascular Disease 22 (10.7%) 3 (10.7%)
Pulmonary Disease 12 (5.9%) 5 (17.9%)
Malignancy 6 (2.9%) 1 (3.6%)
Neural System Diseases 4 (2.1%) 1 (3.6%)
Renal Disease 8 (3.9%) 3 (10.7%)
Autoimmunity Disease 2 (1.1%) 2 (7.1%)
Chronic Liver Disease 4 (2.1%) 0
Rokni et al. BMC Infectious Diseases          (2020) 20:869 Page 4 of 11
Table 4 Laboratory test of 233 patients with COVID-19
Blood routine (Unit, Normal range) Total number N (%) Stat Total patient
N = 233(%)
Survival N = 205 (%) Deceased N = 28 (%)
Leucocyte (×109/L, range 3.5–9.5) 233 (100%) Increased 37 (15.9%) 20 (9.8%) 17 (60.7%)
Decreased 27 (11.6%) 25 (12.2%) 2 (7.1%)
Normal 169 (72.5%) 160 (78%) 9 (32.2%)
Neutrophil (×109/ L, range 1.8–6.3) 233 (100%) Increased 58 (24.9%) 36 (17.6%) 22 (78.6%)
Decreased 17 (7.3%) 16 (7.8%) 1 (3.6%)
Normal 130 (67.8%) 153 (74.6%) 5 (17.8%)
Lymphocyte (×109/ L, range 1.1–3.2) 233 (100%) Decreased 132 (57.6%) 110 (53.7%) 22 (78.6%)
Normal 101 (42.2%) 95 (46.3%) 6 (21.4%)
Platelet (×109/ L, range 125–450) 233 (100%) Increased 7 (3.1%) 6 (2.9%) 1 (3.6%)
Decreased 29 (12.4%) 23 (11.2%) 6 (21.4%)
Normal 197 (84.5%) 176 (85.9%) 21 (75%)
D-Dimer (mg/L; range < 0.55) 34 (15%) Increased 19 (55.9%) 12 (35.3%) 7 (20.6%)
Normal 15 (44.1%) 15 (64.7%) 0
ALT (IU/L, range 0–64) 202 (87%) Increased 22 (10.9%) 19 (10.6%) 3 (13.1%)
Normal 180 (89.1%) 160 (89.4%) 20 (86.9%)
AST (IU/L, range 8–40) 202 (87%) Increased 74 (36.6%) 57 (31.8%) 17 (73.9%)
Normal 128 (63.4%) 122 (68.2%) 6 (26.1%)
ALK.P (IU/L, range 25–320) 195 (84%) Increased 36 (18.5%) 30 (17.2%) 6 (28.6%)
Normal 159 (81.5%) 144 (82.8%) 15 (71.4%)
Total Bilirubin (mg/dL, range 0.4–1.3) 180 (77%) Increased 24 (13.3%) 19 (11.8%) 5 (26.3%)
Decreased 8 (4.4%) 8 (5.1%) 0
Normal 148 (82.3%) 134 (83.1%) 14 (73.7%)
Direct Bilirubin (mg/dL, range 0.1–0.3) 180 (77%) Increased 73 (40.6%) 62 (38.5%) 11 (57.9%)
Decreased 36 (20%) 33 (20.5%) 3 (15.7%)
Normal 71 (39.4%) 66 (41%) 5 (26.4%)
Bun (mg/dL, range 5–24) 225 (97%) Increased 59 (26.2%) 38 (19.1%) 21 (80.8%)
Normal 166 (73.8%) 161 (80.9%) 5 (19.2%)
Creatinine (mg/dL, range 0.5–1.4) 223 (96%) Increased 58 (26%) 40 (20.3%) 18 (69.2%)
Normal 165 (74%) 157 (79.7%) 8 (30.8%)
CPK (IU/L, range 12–160) 183 (79%) Increased 68 (37.2%) 57 (35%) 11 (55%)
Normal 115 (62.8%) 106 (65%) 9 (45%)
LDH (IU/L, range 140–280) 173 (74%) Increased 168 (97.1%) 151 (97.4%) 17 (94%)
Normal 5 (2.9%) 4 (2.6%) 1 (6%)
C-Reactive Protein (mg/L, 0.0–6.0) 233 (100%) Increased 206 (88.4%) 179 (87.3%) 27 (96.4%)
Normal 27 (11.6%) 26 (12.7%) 1 (3.6%)
ESR (mm/h, 2–22) 162 (70%) Increased 139 (85.8%) 124 (90.7%) 15 (100%)
Normal 23 (14.2%) 23 (9.3%) 0
NA (mEq/L, 135–145) 209 (90%) Increased 7 (3.4%) 3 (1.6%) 4 (16%)
Decreased 96 (45.9%) 85 (46.2%) 11 (44%)
Normal 106 (50.7%) 96 (52.2%) 10 (40%)
K (mEq/L, 3.5–5.5) 208 (90%) Increased 3 (1.4%) 0 3 (12%)
Decreased 49 (23.6%) 43 (23.5%) 6 (24%)
Normal 156 (75%) 140 (76.5%) 16 (64%)
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suspected to carry the disease were referred to our cen-
ter over a 3 month period, of which approximately 629
patients had mild/moderate to serious, sometimes fatal,
pneumonia and were hospitalized. Given RT-PCR is
regarded as reference standard method for diagnosis of
SARS-CoV-2 infection [14], the para-clinical data of only
37% (233/629) of patients with positive RT-PCR results
were investigated in the present study.
Human coronavirus is one of the main viral patho-
gens involving respiratory system. SARS-CoV and
MERS-CoV besides four other human coronaviruses
(HCoV-OC43, HCoV-229E, HCoV-NL63 and HCoV-
HKU1) are the main pathogenic viruses belong to
coronavirus family causing either severe respiratory
syndrome or mild upper respiratory disease [15]. The
major SARS-CoV outbreak affected 8422 patients of 29
countries during 2002–2003 [16, 17]. Also, in 2012,
MERS-CoV was emerged in Middle East countries [18].
Although, the genomic sequence of SARS-CoV-2 has
been shown to be relatively different from the six other
coronavirus subtypes but it can be classified as betacor-
onavirus [15]. In case of SARS-CoV and MERS-CoV,
the viruses can be transmitted directly from civets and
dromedary camels to humans, respectively, and bats
were considered as the origin of both viruses, but the
origin of SARS-CoV-2 is still not clear and needs fur-
ther investigation [15, 19]. Rate of transmission is not
exactly documented for SARS-CoV-2; however, human
to human transmission has been evidenced [7, 15]. In
concert with previous reports, it has been revealed that
the clinical manifestations of COVID-19 mimic those
presented in SARS-CoV [4, 7, 15, 20]. Fever and cough
were the most predominant symptoms manifested in
70% and 63% of our patients, respectively. However,
gastrointestinal upsets were infrequently presented
(10%), which suggests a different viral tropism and
pathogenesis in comparison with SARS-CoV, MERS-
CoV, and seasonal influenza [7, 21–23]. The frequency
of afebrile patients suffering from COVID-19 (20%) is
more frequent than in SARS-CoV (1%) and MERS-CoV
infection (2%) [7, 18] implying that presence of fever is
not a trustworthy finding to be focused in case
definition because afebrile patients will be missed. Simi-
lar to previous reports [4, 7, 15], reduced absolute lym-
phocytes count, and elevated level of CRP and ESR
were the main laboratory findings. Damage to T lym-
phocytes might be a contributing factor leading to sub-
stantial decrease in total lymphocytes count and
exacerbation of patient’s status [24] as we observed sta-
tistically significant abnormalities in laboratory findings
(including lymphopenia, elevated NLR, PLR and SII) of
patients who expired (deceased group) when compared
with survival group. In consistent with our result, a pre-
vious study conducted by Liu, et al. [3], documented
NLR as the independent risk factor for prediction of se-
vere illness in patients with SARS-CoV-2 infection and
should thus have rapid access to an ICU if necessary.
So that, in 50% of patients with age ≥ 50 who had
NLR ≥ 3.13, severe form of the disease were observed
[3, 10]. In another study, a correlation between elevated
PLR and the length of hospitalization day was evi-
denced and it has been concluded that if PLR increased
more during treatment, the patient needs longer
hospitalization day and had greater possibility of severe
pneumonia [25]. Furthermore, Chan et al. in a meta-
analysis concluded that NLR and PLR can be served as
independent prognostic markers of disease severity in
COVID-19 [26]. Recently, NLR and PLR have been vali-
dated as prognostic factors in various disorders such as
cardiac conditions, solid tumors, sepsis, pneumonia,
and ARDS [26]. The SII has been proposed as a prog-
nostic indicator in the follow-up of sepsis patients (Sys-
temic immune inflammatory index in sepsis). In
addition, SII has been found to be useful in predicting
the prognosis of small cell lung cancer and hepatocellu-
lar carcinoma [27, 28]. In consistent with previous
study [29], rate of SII was found to be significantly
higher in deceased patients when compared with
survival group, meaning that it can also be used as
predictor of COVID-19 severity and outcome. There-
fore, indicators of systemic inflammation such as
NLR, PLR and SII may be utilized to predict disease
severity, outcome, and mortality of COVID-19. Acute
phase proteins such as CRP, LDH, ferritin,
Table 4 Laboratory test of 233 patients with COVID-19 (Continued)
Blood routine (Unit, Normal range) Total number N (%) Stat Total patient
N = 233(%)
Survival N = 205 (%) Deceased N = 28 (%)
NLR (index, < 5) 233 (100%) Increased 95 (40.8%) 69 (33.7%) 26 (92.9%)
Normal 138 (59.2%) 136 (66.3%) 2 (7.1%)
PLR (index, < 200) 233 (100%) Increased 104 (44.6%) 84 (40.9%) 20 (71.4%)
Normal 129 (55.4%) 121 (59.1%) 8 (28.6%)
SII (index, < 500) 233 (100%) Increased 159 (68.2%) 133 (64.9%) 26 (92.9%)
Normal 74 (31.8%) 72 (35.1%) 2 (7.1%)
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Table 5 Comparison of inclusion indicators in the survival and deceased groups COVID-19
Blood routine (Unit, Normal range) Stat Total (N = 233) Mean ±Std. Err. Mean Sig. (2-tailed)
Leucocyte Count (×109/L, range 3.5–9.5) Deceased 28 12.3 1.17 0.0001**
Survival 205 6.1 0.23
Platelet Count (× 109/ L, range 125–450) Deceased 28 202.1 18.1 0.480
Survival 205 215.9 6.56
Neutrophil Count (×109/ L, range 1.8–6.3) Deceased 28 11.08 1.12 0.0001**
Survival 205 4.69 0.27
Lymphocyte Count (×109/ L, range 1.1–3.2) Deceased 28 0.79 0.07 0.0001**
Survival 205 1.14 0.04
Neutrophil / Lymphocyte Ratio (index, < 5) Deceased 28 19.28 2.93 0.0001**
Survival 205 4.96 0.34
Platelet / Lymphocyte Ratio (index, < 200) Deceased 28 343.8 66.4 0.001*
Survival 205 221.7 10.7
Systematic Inflammatory Index (index, < 500) Deceased 28 3532.9 565.3 0.0001**
Survival 205 1163.5 102.9
BUN (mg/dL, range 5–24) Deceased 26 51.2 7.18 0.0001**
Survival 199 18.3 0.65
Creatinine (mg/dL, range 0.5–1.4) Deceased 26 2.22 0.28 0.0001**
Survival 197 1.16 0.02
C-Reactive Protein (mg/L, 0.0–6.0) Deceased 28 15.0 0.79 0.151
Survival 205 13.2 0.44
SGOT (IU/L, range 8–40) Deceased 23 80.1 20.2 0.0001**
Survival 179 40.6 2.43
SGPT (IU/L, range 0–64) Deceased 23 48.8 12.1 0.176
Survival 179 37.4 2.61
Alkaline Phosphatase (IU/L, range 25–320) Deceased 21 271.5 17.4 0.339
Survival 174 253.1 7.76
Total Bilirubin (mg/dL, range 0.4–1.3) Deceased 19 1.44 0.31 0.004*
Survival 161 0.91 0.05
Direct Bilirubin (mg/dL, range 0.1–0.3) Deceased 19 0.59 0.21 0.007*
Survival 161 0.31 0.03
Creatine Kinase (IU/L, range 12–160) Deceased 20 438.8 169.3 0.315
Survival 163 258.1 48.1
Lactate Dehydrogenase (IU/L, range 140–280) Deceased 18 820.5 122.1 0.001*
Survival 155 534.4 26.5
Sodium (mEq/L, 135–145) Deceased 25 136.40 1.43 0.698
Survival 184 136.04 0.28
Potassium (mEq/L, 3.5–5.5) Deceased 25 4.2 0.17 0.001*
Survival 183 3.9 0.03
ESR (mm/h, 2–22) Deceased 15 56.1 4.81 0.048*
Survival 147 46.3 2.17
D-Dimer (mg/L; range < 0.55) Deceased 7 1.24 0.06 0.001*
Survival 27 0.64 0.08
The values were presented as mean ± SEM. (*P < 0.05, **P ≤ 0.0001)
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procalcitonin, D-Dimer, ESR and IL-6 have also been
well correlated with the disease severity, progression
and poor outcome in COVID-19 [30]. In our study,
CRP protein did not show any significant difference
between survival and deceased groups. By the way,
pathophysiology of COVID-19 is majorly associated
with exaggerated inflammatory responses during the
lung involvement. Lymphocytes, especially T lympho-
cytes, are the main cell to be targeted and consumed
by SARS-CoV-2, as does SARS-CoV [24]. Virus parti-
cles pass across the respiratory mucosa and attack
other cells, resulting in rise of proinflammatory
cytokines and stimulate a cytokine storm and a cas-
cade of immune responses in the body, leading to
lymphocytic apoptosis, changes in peripheral white
blood cells and immune cells such as lymphocytes
[15, 31]. In current study, patients who suffered from
severe form of COVID-19 (31.3%) required ICU
hospitalization and oxygen therapy. Consequently,
ARDS and septic shock progressed rapidly in some of
our patients, which were eventually followed by
multiple organ failure and death. As a result, level of
creatinine, BUN and total/direct bilirubin were signifi-
cantly increased in deceased patients when compared
to alive patients which suggesting acute kidney and
liver injury in our deceased patients similar to what-
ever evidenced in former report [32]. Therefore, early
diagnosis and promptly treatment initiation of critic-
ally ill individuals is issue of crucial importance [15].
Only one patient in our investigation was medical
worker. The mortality rate of SARS-CoV and MERS-
CoV has been reported as more than 10 and 35%,
respectively [33, 34]. The rate of mortality in our
SARS-CoV-2 infected population was 12%, resembling
to previous study [15]. It necessary to be noted that
since patients who had uncomplicated illness and
who did not need medical attention were not in-
cluded in our study, the rate of case fatality in a real
world scenario might be even lower. COVID-19 was
more commonly observed in men than women (64%
vs 36%) in our study. This gender preponderance was
in agreement with previous studies [4, 7, 15]. Also,
higher rate of MERS-CoV and SARS-CoV infection
were documented in males than females [35, 36]. The
lower frequency rate of COVID-19, MERS-CoV and
SARS-CoV infection in females are thought to be at-
tributed to the protection originating from sex hor-
mones and X chromosome, which play contributing
role in innate and adaptive immunity [37]. Addition-
ally, it has been documented that COVID-19 is more
probably to occur in older adult males due to weaker
immune functions particularly those with chronic
underlying diseases [15]. Our patient’s age ranged
from 16 to 90 years with a mean age of 49.8 years.
The data was in consistent with the previous studies
which more and less reported similar mean age [7,
15]. The highest positive rate of COVID-19 RT-PCR
was observed in age group 40–60 years. Since, our
aim was to investigate the COVID-19 patients with
positive RT-PCR as reference method, of 629 hospi-
talized patients who were clinically suspected cases of
COVID-19 and also had initial positive CT scan sug-
gesting COVID-19, only small quantity of our subjects
had positive RT-PCR assay suggesting two scenarios:
first, it may be indeed be true to say that the sensitiv-
ity rate of RT-PCR is as low as 37% which somehow
has been also demonstrated in previous studies and
may be justified by a list of confounding factors
which is regarded to influence the result of RT-PCR
and lead to false-negative including: improperly col-
lected, transported or handled specimens, presence of
amplification inhibitors in the specimen or inadequate
numbers of organisms [14, 38, 39]. Second, due to
the overlap of CT imaging patterns between COVID-
19 and other viral pneumonia, false-positive cases of
COVID-19 may be identified on chest CT scan [14].
Nevertheless, given the rapidly spreading of COVID-
19, the priority should be to identify and isolate any
suspicious CT scan case in order to administer appro-
priate treatment. By the way, in the context of disease
control, some false-positive cases may be acceptable
[14]. Therefore, one negative result of RT-PCR does




N = 176 (%)
Deceased










Clear 15 (8.5%) 0 15 (7.1%) 0 0 0 15 (7.1%)
GGO 63 (35.8%) 0 0 22 (10.5%) 24 (11.5%) 17 (8.3%) 63 (30.3%)
Consolidation 20 (11.4%) 3 (10.7%) 0 5 (2.5%) 13 (6.4%) 5 (2.5%) 23 (11.4%)
Mixed 78 (44.3%) 25 (89.3%) 0 5 (2.5%) 95 (46.9%) 3 (1.8%) 103 (51.2%)
Total 176 (100%) 28 (100%) 15 (7.1%) 32 (15.5%) 132 (64.8%) 25 (12.6%) 204 (100%)
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not rule out SARS-CoV-2 infection and should not be
used as the sole basis for patient management deci-
sions and treatment.
Conclusions
As a result, serially performance of RT-PCR test along
with CT scans is recommended. In suspected patients
with negative RT-PCR tests, a combination of a history
of direct contact with proven cases, clinical manifesta-
tions and typical CT imaging features should be collect-
ively used to detect patients with COVID-19. Elevated
NLR, PLR and SII can be considered as prognostic and
risk stratifying factor of severe form of disease.
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